Skip to Main Content

Is pharma about to have its Big Tobacco moment? Are we overestimating human genetics? And can sales reps rap?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, Boston Globe reporter Jonathan Saltzman joins us to discuss the case against Insys Therapeutics, the maker of a powerful painkiller now accused of running a nationwide racketeering scheme. Then Dr. Laura Esserman of the University of California, San Francisco, comes on to break down the debate over genetic testing for cancer risk. And then we give you the need-to-know on an upcoming Senate hearing that will see seven pharma executives get grilled on the rising cost of medicines in the U.S.

For more on what we cover, here’s the latest on the Insys trial, and here’s a preview of the Senate hearing.


We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts. And stay tuned for a special episode tomorrow on a newly public sealed deposition that shows how Purdue’s Dr. Richard Sackler embraced a plan to conceal OxyContin’s strength from doctors.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].


Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].